Co-delivery of RNA adjuvants and mRNA vaccines
| Reference number | |
| Coordinator | RISE Research Institutes of Sweden AB - Biovetenskap och hälsa |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | October 2024 - December 2025 |
| Status | Completed |
| Venture | Preparation projects for international application within health |
| Call | Towards deeper collaboration with UK and USA partners within Health and Life Science |
Important results from the project
Yes, the goals were met. The project developed and analyzed innovative nanoparticle systems for RNA delivery and achieved proof-of-concept for co-delivery of mRNA vaccines and RNA adjuvants. It also established international collaboration, performed IPR analysis, and identified funding opportunities. Other key results include optimized particle size, graphene oxide and chitosan functionalization, and strategies for controlled release.
Expected long term effects
The project is expected to have long-term impacts by establishing next-generation RNA delivery systems that are safer, more efficient and patient-friendly. The technology could revolutionize the treatment of cancer, infectious diseases and chronic inflammatory conditions, reduce the need for booster doses and contribute to global health through scalable, cost-effective solutions. Alwso, the project strengthens international collaborations and creates the basis for future research consortia.
Approach and implementation
The project was carried out through 3 work packages: project management and IPR analysis, development and screening of nanoparticle systems for RNA adjuvants and mRNA vaccines, and strategies for long-term funding. Activities included design, functionalization, and characterization of carrier particles, optimization of particle size and charge, and regular meetings with international partners for coordination, knowledge exchange, and planning future consortia.